TOKYO, LONDON and NOVATO, California, February 23, 2018 /PRNewswire/ —
Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease
Crysvita Acknowledged by European Medicines Agency as an Outstanding Contribution to PublicHealth
Kyowa Hakko…
